Technology News and Research

RSS

Poll finds health industry 'not adequately prepared' to protect patients' digital records

Reuters reports on a new poll of health executives that indicates that the industry is not adequately prepared to protect patients' digital health records. Still, according to the Boston Globe, Dr. David Blumenthal, offered a positive view of medical technology in a Wednesday night speech, saying that electronic medical records made him a better doctor.

23 Sep 2011

SANUWAVE announces dermaPACE Phase III trial results on diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the Company's dermaPACE device will be the subject of a presentation at Plastic Surgery 2011, the American Society of Plastic Surgeons' National Meeting being held September 23-27 in Denver.

23 Sep 2011

Researchers compare safety and effectiveness of cryotherapy, salicylic acid for verrucae

Research has shown no evidence of a difference in clearance rates between patient self-treatment and treatment given by healthcare professional for verrucae.

23 Sep 2011

STAAR's new Visian ICL with CentraFLOW technology showcased at ESCRS congress

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were featured prominently in twice as many presentations at the 2011 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) as those on the ICL during last year's Congress.

23 Sep 2011

CoPlex, Hawthorn sign license agreement for hawAD14 Alzheimer's drug

CoPlex Therapeutics has signed an exclusive global license agreement with Hawthorn Pharmaceuticals to develop and commercialize hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

23 Sep 2011

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.

23 Sep 2011

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

23 Sep 2011

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

The Cedars-Sinai Regenerative Medicine Institute has opened a new Induced Pluripotent Stem Cell (iPSC) Core Facility to produce powerful cells capable of making all tissues of the body from adult human skin cells.

23 Sep 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

23 Sep 2011

Cambridge Heart enters agreement with EO Medical for MTWA technology

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that it has executed an exclusive agreement with EO Medical Pte Ltd to distribute its HearTwave II System and proprietary Microvolt T-Wave Alternans (MTWA) software and Micro-V Alternans Sensors in Singapore upon regulatory approval.

22 Sep 2011

U.N. meeting on NCDs concludes with pledges to fight chronic diseases

World leaders on Tuesday "pledged to take wide-ranging action to prevent millions of deaths from cancer, diabetes, and heart and lung disease by tackling the key causes -- smoking, excessive drinking, lack of exercise and unhealthy diets dominated by fast food," but the "declaration approved at the first-ever General Assembly meeting on chronic diseases which ended Tuesday left unanswered the question of coordinating an international response to what the leaders called 'a challenge of epidemic proportions,'" the Associated Press/CBS News reports.

22 Sep 2011

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt's Macular Dystrophy using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

22 Sep 2011

Neogen develops quick and easy new test for aflatoxin

Neogen Corporation has developed a quick and easy new test for aflatoxin, a toxin considered by many to be the most potent, naturally-occurring carcinogen. The toxin is a by-product of mold growth in a wide range of commodities, including corn.

22 Sep 2011

Zymeworks announces completion of $8.1M financing

Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced the completion of a financing totaling $8.1 million.

22 Sep 2011

OPTOS to acquire ophthalmic instrumentation business from OPKO

OPKO Health, Inc. has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, manufacture and marketing of devices to image the retina of the eye. Optos will pay OPKO $17.5 million in cash at closing, plus future royalties.

22 Sep 2011

InSightec's ExAblate Neuro system may treat chronic brain disorders

InSightec Ltd., the global leader in MR guided Focused Ultrasound (MRgFUS) technology, announced today that its investigational ExAblate(R) Neuro system has been used in clinical studies to treat 30 patients suffering from chronic neurological disorders.

22 Sep 2011

Stanford Hospital & Clinics inaugurates new Brain Tumor Center

Today, Stanford Hospital & Clinics inaugurates its new Brain Tumor Center, framing its considerable corps of top-notch specialists into a treatment team driven by expertise, experience and compassion.

22 Sep 2011

Sapheon's new varicose vein closure system receives European CE Mark approval

Sapheon Inc. announced that it has received CE Mark approval for its new approach to the treatment of varicose veins caused by venous reflux disease.

22 Sep 2011

Zinc plays a critical role in regulating communication between brain cells

Zinc has been found to play a critical role in regulating communication between cells in the brain, possibly governing the formation of memories and controlling the occurrence of epileptic seizures.

22 Sep 2011

Scientists discover 10 types of unique proteins in patients with stroke or heart attack

A simple blood test is all it could take to tell if you are going to have a heart attack or stroke. A team of international scientists have discovered more than 10 types of unique proteins which are commonly present in the blood of a person who recently suffered a stroke or heart attack.

22 Sep 2011